Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: Evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Ovarian cancer is the most lethal gynecological malignancy, characterized by a high rate of chemoresistance. Current treatment strategies for ovarian cancer focus on novel drug combinations of cytotoxic agents and molecular targeted agents or novel drug delivery strategies that often involve intraperitoneal (IP) injection. Poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) micelles were loaded with paclitaxel (cytotoxic agent), cyclopamine (hedgehog inhibitor), and gossypol (Bcl-2 inhibitor). After physicochemical studies focusing on combination drug solubilization, 3-drug PEG-b-PCL micelles were evaluated in vitro in 2-D and 3-D cell culture and in vivo in xenograft models of ovarian cancer, tracking bioluminescence signals from ES-2 and SKOV3 human ovarian cancer cell lines after IP injection. 3-drug PEG-b-PCL micelles were not significantly more potent in 2-D cell culture in comparison to paclitaxel; however, they disaggregated ES-2 tumor spheroids, whereas single drugs or 2-drug combinations only slowed growth of ES-2 tumor spheroids or had no noticeable effects. In ES-2 and SKOV3 xenograft models, 3-drug PEG-b-PCL micelles had significantly less tumor burden than paclitaxel based on bioluminescence imaging, 3′-deoxy-3′-18F-fluorothymidine (18F-FLT) PET imaging, and overall survival. 18F-FLT-PET images clearly showed that 3-drug PEG-b-PCL micelles dramatically reduce tumor volumes over paclitaxel and vehicle controls. In summary, PEG-b-PCL micelles enable the IP combination drug delivery of paclitaxel, cyclopamine and gossypol, resulting in tumor growth inhibition and prolonged survival over paclitaxel alone. These results validate a novel treatment strategy for ovarian cancer based on drug combinations of cytotoxic agents and molecular targeted agents, delivered concurrently by a nanoscale drug delivery system, e.g. PEG-b-PCL micelles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spheroid-based drug screen: Considerations and practical approach
Friedrich, J., Seidel, C., Ebner, R., & Kunz-Schughart, L. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.226 · Cited by 1,742 · cited 1×
“ES-2-luc cells (1000 cells/well) were suspended in agarose-coated 96-well plates and incubated for 4 days to generate 3-D tumor spheroids [16].”
MethodSodek, K. L., Ringuette, M. J., & Brown, T. J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24188 · Cited by 248
A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs
Shin, H.-C., Alani, A. W. G., Cho, H., Bae, Y., Kolesar, J. M., & Kwon, G. S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2000549 · Cited by 126 · cited 1×
“Our prior studies on 3-drug poly(ethylene glycol)-blockpoly(D,L-lactic acid) micelles showed a correlation between the t1/2 values for in vitro multi-drug release and octanol-water partition coefficients (log P) [29].”
MethodSelf-citation
Cited by
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application
Grossen, P., Witzigmann, D., Sieber, S., & Huwyler, J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.028 · Cited by 496
Polymeric nanoparticles: the future of nanomedicine
Banik, B. L., Fattahi, P., & Brown, J. L. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1364 · Cited by 485
Nanocarrier for Poorly Water-Soluble Anticancer Drugs—Barriers of Translation and Solutions
Narvekar, M., Xue, H. Y., Eoh, J. Y., & Wong, H. L. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0107-x · Cited by 257
Polymeric Micelles for Multi-Drug Delivery in Cancer
Cho, H., Lai, T. C., Tomoda, K., & Kwon, G. S. (2015) · AAPS PharmSciTech · doi:10.1208/s12249-014-0251-3 · Cited by 159
Self-citation
Metadata
- Authors
- Cho, H., Lai, T. C., & Kwon, G. S.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 166
- Issue
- 1
- Pages
- 1-9
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2157637866
- Cited by
- 112
- References
- 3
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.